Bullish
Intellia Therapeutics (NTLA) is drawing attention after reporting positive Phase 3 data for its hereditary angioedema treatment, lonvoguran ziclumeran...
Bullish
Intellia Therapeutics (NASDAQ:NTLA) saw a 25% stock surge due to investor optimism over upcoming Phase 3 HAELO study data for its gene-editing treatme...
Intellia Therapeutics (NTLA) is drawing attention as it approaches the release of Phase 3 HAELO trial data for its gene editing therapy, lonvo-z, in h...
Intellia Therapeutics (NTLA) shares rose 10.6% following positive Phase III results for its CRISPR therapy, lonvoguran ziclumeran, and the FDA lifting...
Neutral
Intellia Therapeutics continues to attract investor attention as it advances its CRISPR-based gene-editing pipeline. The company focuses on both in vi...
Intellia Therapeutics (NTLA) reported a Q1 2026 net loss of US$96.2 million on US$15.0 million revenue, similar to the previous quarter, raising quest...